Medical Oncologist
Targeted treatment for sarcoma
Targeted Therapy for — Sarcoma
Targeted therapy for sarcoma works only when your tumour has a specific mutation or gene fusion that a drug is designed to block. Your exact subtype — and what molecular testing finds in your tissue — determines whether this approach is relevant to you.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Subtype matters most — There are over 70 sarcoma subtypes. Which one you have determines whether a targeted drug exists at all.
- Molecular testing first — A drug cannot be recommended until your tumour tissue is tested for the mutations that predict response.
- GIST has the most options — Gastrointestinal stromal tumour has more approved targeted drugs than any other sarcoma subtype.
- Most sarcomas lack a clear target — For the majority of sarcoma subtypes, chemotherapy remains the backbone of treatment, not targeted therapy.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Targeted therapy for sarcoma works only when your tumour carries a specific mutation or gene fusion that a drug can block. Which drug applies to you depends on your exact sarcoma subtype and the results of molecular testing. Most sarcoma subtypes do not yet have an approved targeted agent.
Which sarcoma subtypes have an approved targeted drug?
GIST — gastrointestinal stromal tumour — has the most established targeted drugs of any sarcoma subtype. KIT and PDGFRA mutations drive almost all GIST cases, and NCCN and ESMO guidelines recommend tyrosine kinase inhibitors as the standard approach for most patients.
A small number of other subtypes also have drugs supported by evidence. Inflammatory myofibroblastic tumour with an ALK rearrangement can respond to ALK inhibitors. Dermatofibrosarcoma protuberans, which carries a PDGFB gene rearrangement in most cases, frequently responds to imatinib. Any sarcoma with an NTRK gene fusion qualifies for TRK inhibitor therapy under NCCN guidance, regardless of histological subtype.
For the majority of sarcoma subtypes — including most bone sarcomas and many soft tissue types — there is currently no approved targeted drug. Chemotherapy, sometimes with radiation or surgery, remains the primary treatment.
Which mutations is your oncologist likely to test for?
- KIT and PDGFRA (GIST)Tested in all GIST cases. The specific mutation exon guides which drug is recommended and predicts how likely it is to respond.
- NTRK1, NTRK2, NTRK3 fusions (any subtype)Tested across sarcoma subtypes. A positive result makes you eligible for TRK inhibitor therapy regardless of where the tumour started.
- ALK rearrangement (inflammatory myofibroblastic tumour)Tested when IMT is suspected. ALK inhibitors have shown activity in ALK-positive cases.
- PDGFB rearrangement (dermatofibrosarcoma protuberans)This rearrangement is present in most DFSP cases and predicts response to imatinib.
- MDM2 and CDK4 amplification (liposarcoma)Tested in dedifferentiated liposarcoma. Drugs targeting these pathways are under clinical investigation; a positive result may open trial eligibility.
- SDH gene alterations (SDH-deficient GIST)A small group of GIST cases lack KIT and PDGFRA mutations and instead carry SDH deficiency. These behave differently and do not respond to standard GIST drugs.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What if your sarcoma has no targetable mutation?
Being told there is no targetable mutation is not a judgement on how serious your cancer is. It means the biology of your tumour does not fit the drugs currently available — and that your team will move to the treatments that do have evidence for your subtype.
For most sarcoma subtypes, that means chemotherapy, sometimes combined with other agents. ESMO guidelines identify active regimens for the majority of histological types, and chemotherapy can be effective for sarcoma.
Clinical trials are worth asking about. Sarcoma is an active area of research, and some trials offer access to drugs showing early promise that are not yet approved.
How does molecular testing work before your treatment starts?
Biopsy tissue is collected
Your sarcoma diagnosis requires a biopsy. That same tissue block is almost always used for molecular testing, so a separate procedure is rarely needed.
Molecular profiling is performed
The laboratory tests your tissue for specific mutations, gene fusions, and amplifications relevant to your subtype. This takes longer than routine pathology — usually one to two weeks.
Results are reviewed by your oncologist
Your oncologist goes through the molecular report. Complex or unusual cases may be discussed at a molecular tumour board, where specialists review the findings together.
A treatment plan is formed
If a targetable mutation is found, the relevant drug is considered. If not, the evidence-based treatment for your histological subtype is recommended.
Did you know?
NTRK gene fusions are rare across most solid tumours but appear in a proportion of certain sarcoma types, including infantile fibrosarcoma.
NCCN and ESMO guidance recommends TRK inhibitor therapy for any NTRK fusion-positive solid tumour regardless of where it started — one of the first treatments approved based on a molecular marker rather than the organ of origin.
Source: NCCN Guidelines for Soft Tissue Sarcoma; ESMO Clinical Practice Guidelines for Soft Tissue and Visceral Sarcomas
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Do I need molecular testing even if I already have a sarcoma diagnosis?
Yes, in most cases. The histological diagnosis — the name of your sarcoma type — is not enough on its own to decide treatment. Molecular testing tells your oncologist whether your tumour has a mutation or fusion that a drug can target. Without it, a targeted option could be missed entirely. If you have not been told whether molecular profiling was done on your tissue, ask your oncologist directly.
Is GIST the only sarcoma where targeted therapy is the standard first treatment?
GIST is the clearest example, and NCCN and ESMO guidelines establish tyrosine kinase inhibitors as the standard of care for most GIST patients. A small number of other subtypes also have targeted options — particularly for NTRK fusions, ALK rearrangements and PDGFB rearrangements — but these are far less common. For the majority of soft tissue and bone sarcoma subtypes, targeted therapy is not the first-line standard.
How long does molecular testing take?
Usually one to two weeks from when the laboratory receives the tissue sample, though turnaround varies. If your original biopsy tissue needs to travel to a specialist laboratory, or if the sample is very small, it may take longer. Ask your oncologist when the sample was sent and when results are expected, so you are not waiting without a timeline.
Are targeted therapy drugs for sarcoma available in India?
Several are. Imatinib, for example, is approved by CDSCO and widely used for GIST across India. Availability and cost vary by drug and treatment centre. For newer agents such as TRK inhibitors, your oncologist will advise whether they are available locally, whether a named-patient route applies, or whether a clinical trial is the better path.
Can targeted therapy be used alongside chemotherapy for sarcoma?
In most sarcoma contexts, targeted therapy and chemotherapy are used separately rather than together. The drugs in current use were approved as single agents, and combining them can increase side effects without a clear benefit for most subtypes. Whether this applies to your situation depends on your subtype and what is being considered; your oncologist will explain the plan and the evidence behind it.
What should I ask at my next appointment about molecular testing?
Ask whether molecular profiling has been done on your tumour tissue and what it showed. If it has not been done, ask whether it is recommended for your subtype. Ask which specific mutations were tested, not just whether a report is back. If a targeted drug is being considered, ask what the evidence base is for your specific mutation and whether it is approved or being offered through a trial. Written copies of your molecular report are reasonable to request.